Opdivo, a product of Bristol-Myers Squibb, has become the sole PD-1 inhibitor to successfully increase the overall survival of patients living with advanced renal cell carcinoma (RCC). The U.S. Food and Drug Administration (FDA) green-lighted Opdivo, an intravenous treatment, for RCC patients who had been previously treated with anti-angiogenic therapy.
Angiogenesis is the process through which new blood vessels form from pre-existing vessels.
Opdivo was put through a Checkmate -025 trial, during which patients treated with the drug lived an average of 25 months compared to patients who were treated with other therapies, who lived an average of 19.6 months.
The study also showed Opdivo to be safe for use.
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
